Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/cancer-diagnostics-iEkwQmL9bB
References (48)
-
S Paik, S Shak, G Tang (2004)
Expression of the 21 genes in the recurrence score assay and Prediction of clinical benefit from Tamoxifen in NSABP study B14 and Chemotherapy in NSABP study B-20Breast Cancer Res Treat, 88
-
H. Shigematsu, Li Lin, Takao Takahashi, M. Nomura, Makoto Suzuki, I. Wistuba, K. Fong, Hue Lee, S. Toyooka, N. Shimizu, T. Fujisawa, Ziding Feng, J. Roth, J. Herz, J. Minna, A. Gazdar (2006)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.Journal of the National Cancer Institute, 97 5
-
M. Vijver, Yudong He, L. Veer, H. Dai, A. Hart, D. Voskuil, G. Schreiber, J. Peterse, C. Roberts, M. Marton, M. Parrish, D. Atsma, A. Witteveen, A. Glas, L. Delahaye, Tony Velde, H. Bartelink, S. Rodenhuis, E. Rutgers, S. Friend, René Bernards (2002)
A gene-expression signature as a predictor of survival in breast cancer.The New England journal of medicine, 347 25
-
TJ Lynch, DW Bell, R Sordella (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med, 350
-
T. Sørlie, C. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. Eisen, M. Rijn, S. Jeffrey, T. Thorsen, H. Quist, J. Matese, P. Brown, D. Botstein, P. Lønning, A. Børresen-Dale (2001)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 98
-
S. Braun, Manfred Mülller, F. Hepp, G. Schlimok, G. Riethmüller, K. Pantel (1996)
Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.Journal of the National Cancer Institute, 90 14
-
J. Mansi, H. Gogas, A.J. Biss, J. Gazet, U. Berger, R. Coombes (1999)
Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up studyThe Lancet, 354
-
MC Paterson, KD Dietrich, J Danyluk (1991)
Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancerCancer Res, 51
-
G Gebauer, T Fehm, E Merkle (2001)
Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-upJ Clin Oncol, 19
-
R. Betensky, D. Louis, J. Cairncross (2002)
Influence of unrecognized molecular heterogeneity on randomized clinical trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 10
-
F. Jänicke, A. Prechtl, C. Thomssen, N. Harbeck, C. Meisner, M. Untch, C. Sweep, H. Selbmann, H. Graeff, M. Schmitt (2001)
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.Journal of the National Cancer Institute, 93 12
-
J. Paez, P. Jänne, Jeffrey Lee, Sean Tracy, H. Greulich, S. Gabriel, P. Herman, F. Kaye, N. Lindeman, T. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. Eck, W. Sellers, B. Johnson, M. Meyerson (2004)
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 304
-
H. Takeuchi, A. Fujimoto, D. Hoon (2004)
Detection of Mitochondrial DNA Alterations in Plasma of Malignant Melanoma PatientsAnnals of the New York Academy of Sciences, 1022
-
D. Slamon, G. Clark, S. Wong, W. Levin, A. Ullrich, W. McGuire (1987)
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science, 235 4785
-
MH Cohen, GA Williams, R Sridhara (2004)
United States food and drug administration drug approval summary: Gefitinib (ZD1839; Iressa) tabletsClin Cancer Res, 10
-
M. Cristofanilli, D. Hayes, G. Budd, M. Ellis, A. Stopeck, J. Reuben, G. Doyle, J. Matera, W. Allard, M. Miller, H. Fritsche, G. Hortobagyi, L. Terstappen (2005)
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 7
-
N Harbeck, RE Kates, MP Look (2002)
Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424)Cancer Res, 62
-
RL White, LG Wilke (2004)
Update on the NSABP and ACOSOG breast cancer sentinel node trialsAm Surg, 70
-
F. Cappuzzo, F. Hirsch, E. Rossi, S. Bartolini, G. Ceresoli, L. Bemis, J. Haney, S. Witta, K. Danenberg, I. Domenichini, V. Ludovini, E. Magrini, V. Gregorc, C. Doglioni, A. Sidoni, M. Tonato, W. Franklin, L. Crinò, P. Bunn, M. Varella-Garcia (2005)
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.Journal of the National Cancer Institute, 97 9
-
B Gerber, A Krause, H Muller (2001)
Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factorsJ Clin Oncol, 19
-
M. Cronin, M. Pho, D. Dutta, J. Stephans, S. Shak, M. Kiefer, J. Esteban, J. Baker (2004)
Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay.The American journal of pathology, 164 1
-
S Braun, BS Cevatli, C Assemi (2001)
Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapyJ Clin Oncol, 19
-
B. Fisher, Jong-Hyeon Jeong, J. Bryant, S. Anderson, J. Dignam, E. Fisher, N. Wolmark (2004)
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trialsThe Lancet, 364
-
S. Braun, K. Pantel, P. Müller, W. Janni, F. Hepp, C. Kentenich, Stephan Gastroph, Artur Wischnik, T. Dimpfl, Günter Kindermann, G. Riethmüller, G. Schlimok (2000)
Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.The New England journal of medicine, 342 8
-
S. Paik, J. Bryant, C. Park, B. Fisher, E. Tan-chiu, D. Hyams, Edwin Fisher, M. Lippman, D. Wickerham, N. Wolmark (1998)
erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.Journal of the National Cancer Institute, 90 18
-
JMS Bartlett (2005)
Pharmacodiagnostic testing in breast cancer: focus on HER2 and trastuzumab therapyAm J Pharmacogenomics, 5
-
R. Birbe, J. Palazzo, R. Walters, D. Weinberg, S. Schulz, S. Waldman (2005)
Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract.Human pathology, 36 2
-
S. Paik, S. Shak, G. Tang, Chungyeul Kim, J. Baker, M. Cronin, F. Baehner, M. Walker, D. Watson, T. Park, W. Hiller, E. Fisher, D. Wickerham, J. Bryant, N. Wolmark, Genomic Health, Redwood City, S. Francisco (2004)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.The New England journal of medicine, 351 27
-
LA Habel, CP Quesenberry, MK Jacobs (2004)
A large case-control study of gene expression and breast cancer death in the Northern California Kaiser Permanente populationBreast Cancer Res Treat, 88
-
P. Roche, V. Suman, R. Jenkins, N. Davidson, S. Martino, P. Kaufman, F. Addo, B. Murphy, J. Ingle, E. Perez (2002)
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831.Journal of the National Cancer Institute, 94 11
-
R. Cote, H. Fpeterson, B. Chaiwun, R. Gelber, A. Goldhirsch, M. Castiglione‐Gertsch, B. Gusterson, Neville Am (1999)
Role of immunohistochemical detection of lymph-node metastases in management of breast cancerThe Lancet, 354
-
N. Harbeck, R. Kates, M. Schmitt (2002)
Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 4
-
RJ Cote, HF Peterson, B Chaiwun (1999)
Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study GroupLancet, 354
-
Per Lønning, Therese Sørlie, C. Perou, Pat Brown, D. Botstein, A. Børresen-Dale (2001)
Microarrays in primary breast cancer--lessons from chemotherapy studies.Endocrine-related cancer, 8 3
-
T. Fleming, M. Watson (2000)
Mammaglobin, a Breast‐Specific Gene, and Its Utility as a Marker for Breast CancerAnnals of the New York Academy of Sciences, 923
-
C. Perou, T. Sørlie, M. Eisen, M. Rijn, S. Jeffrey, Christian Rees, J. Pollack, D. Ross, H. Johnsen, L. Akslen, Ø. Fluge, Alexander Pergamenschikov, Cheryl Williams, Shirley Zhu, P. Lønning, A. Børresen-Dale, P. Brown, D. Botstein (2000)
Molecular portraits of human breast tumoursNature, 406
-
MP Look, WL Putten, MJ Duffy (2002)
J Natl Cancer Inst -
A Zippelius, R Lutterbuse, G Riethmuller (2000)
Analytical variables of reverse transcription-polymerase chain reaction-based detection of disseminated prostate cancer cellsClin Cancer Res, 6
-
J. Bartlett (2005)
Pharmacodiagnostic Testing in Breast CancerAmerican Journal of Pharmacogenomics, 5
-
M. Cohen, Grant Williams, R. Sridhara, Gang Chen, W. Mcguinn, D. Morse, S. Abraham, Atiqur Rahman, Chen Liang, R. Lostritto, A. Baird, R. Pazdur (2004)
United States Food and Drug Administration Drug Approval SummaryClinical Cancer Research, 10
-
Edward Korn, Lisa McShane, J. Troendle, A. Rosenwald, Richard Simon (2002)
Identifying pre-post chemotherapy differences in gene expression in breast tumours: a statistical method appropriate for this aimBritish Journal of Cancer, 86
-
F. Barlesi, C. Tchouhadjian, C. Doddoli, P. Villani, L. Greillier, J. Kleisbauer, P. Thomas, P. Astoul (2005)
Gefitinib (ZD1839, Iressa®) in non‐small‐cell lung cancer: a review of clinical trials from a daily practice perspectiveFundamental & Clinical Pharmacology, 19
-
S. Paik, J. Bryant, E. Tan-chiu, E. Romond, W. Hiller, Kyeongmee Park, A. Brown, G. Yothers, S. Anderson, Roy Smith, D. Wickerham, N. Wolmark (2002)
Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.Journal of the National Cancer Institute, 94 11
-
K. McMasters, R. Noyes, D. Reintgen, James Goydos, P. Beitsch, B. Davidson, J. Sussman, J. Gershenwald, M. Ross (2004)
Lessons learned from the Sunbelt Melanoma TrialJournal of Surgical Oncology, 86
-
Daniel Jones (2004)
Anticancer drugs: To the rescue?Nature Reviews Drug Discovery, 3
-
A. Thor, A. Thor, D. Berry, D. Budman, H. Muss, T. Kute, I. Henderson, M. Barcos, C. Cirrincione, S. Edgerton, C. Allred, L. Norton, E. Liu, E. Liu (1998)
erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.Journal of the National Cancer Institute, 90 18
-
D. Slamon, W. Godolphin, L. Jones, J. Holt, Steven Wong, D. Keith, W. Levin, S. Stuart, J. Udove, A. Ullrich, M. Press (1989)
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.Science, 244 4905
-
A. Tos, I. Ellis (2005)
Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods?European journal of cancer, 41 10
- Publisher
- Springer Journals
- Copyright
- Copyright © 2005 by Adis Data Information BV
- Subject
- Pharmacy; Pharmacy
- ISSN
- 1175-2203
- DOI
- 10.2165/00129785-200505060-00003
- Publisher site
- See Article on Publisher Site
Abstract
A new diagnostic tool must pass three major tests before it is adopted for routine clinical use. First, the tool must be robust and reproducible; second, the clinical value of the tool must be proven, i.e. the tool should reliably trigger a clinical decision that results in patient benefit; and, third, the clinical community has to be convinced of the need for this tool and the benefits it affords. Another factor that can influence the adoption of new tools relates to the cost and the vagaries of insurance reimbursement.
Journal
American Journal of Pharmacogenomics – Springer Journals
Published: Aug 21, 2012